Compounds > fh535
Page last updated: 2024-12-10

fh535

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

FH535: inhibits Wnt signaling [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3463933
CHEMBL ID2363137
CHEBI ID125569
SCHEMBL ID15318105
MeSH IDM0577774

Synonyms (43)

Synonym
CBMICRO_011295
BIM-0011242.P001
STK079761
2,5-dichloro-n-(2-methyl-4-nitrophenyl)benzenesulfonamide
CHEBI:125569
AKOS003980135
CB14399
smsf0005619
FT-0672020
108409-83-2
fh535
n-(2-methyl-4-nitrophenyl)-2,5-dichlorobenzenesulfonamide
beta-catenin/tcf inhibitor, fh535
S7484
BRD-K48112880-001-01-5
CHEMBL2363137 ,
CCG-208119
HY-15721
CS-1538
c13h10cl2n2o4s
SCHEMBL15318105
fh 535
HB0288
AC-31439
DTXSID60392716
Q27216183
J-002138
EX-A388
fh535, >=98% (hplc)
HMS3653N07
fh-535
AS-60177
2,5-dichloro-n-(2-methyl-4-nitrophenyl)benzene-1-sulfonamide
mfcd01212888
SW219729-1
n-[2-methyl-4-nitrophenyl]-2,5-dichlorobenzenesulfonamide
BCP09634
SB19433
2,5-dichloro-n-(2-methyl-4-nitrophenyl)-benzenesulfonamide
nsc-778746
nsc778746
bdbm50509999
beta -catenin/tcf inhibitor, fh535

Research Excerpts

Actions

ExcerptReferenceRelevance
"FH535 was shown to increase CSC-induced cytotoxicity and depress β-catenin expression."( FH535 potentiation of cigarette smoke condensate cytotoxicity is associated with changes in β-catenin and EGR-1 signaling.
Polk, WW, )		2.3

Compound-Compound Interactions

ExcerptReferenceRelevance
" The purpose of this study was to investigate the inhibitory effect of miR-200a mimics, FH535 combined with taxol on proliferation and invasion of human gastric cancer cell lines SGC-7901 and BGC-823."( Effects of miR-200a and FH535 combined with taxol on proliferation and invasion of gastric cancer.
Du, P; Han, L; Jiang, K; Liu, X; Zhang, A; Zhang, Q, 2018)		1.01
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
morphogenesis of an epitheliumNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
cerebrospinal fluid circulationNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
renal sodium ion transportNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
plasma membrane organizationNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
nuclear migrationNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
sensory perception of soundNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
negative regulation of cell population proliferationNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
regulation of cell shapeNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
regulation of cell sizeNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
fibroblast migrationNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
negative regulation of fibroblast migrationNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
negative regulation of sodium ion transportNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
Wnt signaling pathwayNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
gland morphogenesisNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
microvillus assemblyNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
actin cytoskeleton organizationNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
intracellular phosphate ion homeostasisNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
bile acid secretionNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
glutathione transportNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
positive regulation of monoatomic ion transmembrane transportNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
cilium organizationNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
establishment of epithelial cell apical/basal polarityNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
maintenance of epithelial cell apical/basal polarityNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
regulation of protein kinase activityNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
negative regulation of mitotic cell cycleNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
establishment of Golgi localizationNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
gamma-aminobutyric acid importNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
auditory receptor cell stereocilium organizationNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
protein-containing complex assemblyNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
renal absorptionNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
protein localization to plasma membraneNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
renal phosphate ion absorptionNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
import across plasma membraneNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
transport across blood-brain barrierNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
regulation of renal phosphate excretionNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
gamma-aminobutyric acid transmembrane transporter activityNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
signaling receptor bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
protein bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
beta-catenin bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
chloride channel regulator activityNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
phosphatase bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
PDZ domain bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
beta-2 adrenergic receptor bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
type 2 metabotropic glutamate receptor bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
type 3 metabotropic glutamate receptor bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
identical protein bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
transmembrane transporter bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
protein-containing complex bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
myosin II bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
dopamine receptor bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
growth factor receptor bindingNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
channel activator activityNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
protein-membrane adaptor activityNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
nucleusNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
plasma membrane protein complexNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
ruffleNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
cytoplasmNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
microvillusNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
endomembrane systemNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
actin cytoskeletonNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
membraneNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
apical plasma membraneNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
filopodiumNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
brush border membraneNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
microvillus membraneNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
vesicleNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
stereocilium tipNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
perinuclear region of cytoplasmNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
extracellular exosomeNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
cell peripheryNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
sperm midpieceNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
apical plasma membraneNa(+)/H(+) exchange regulatory cofactor NHE-RF1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1243334Inhibition of Wnt/beta catenin in human HuH7 cells assessed as decrease in TCF/LEF-dependent promoter activation at 10 uM after 36 hrs by TOPFlash luciferase reporter gene assay relative to control2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
N-Aryl benzenesulfonamide inhibitors of [3H]-thymidine incorporation and β-catenin signaling in human hepatocyte-derived Huh-7 carcinoma cells.
AID1528297Induction of mitochondrial membrane potential disruption in human DLD1 cells measured after 2 hrs by TMRM staining based fluorescence microscopic analysis2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
AID1528286Activation of AMPK in human LS174T cells assessed as reduction in ACC phosphorylation at S79 residue at 3 uM measured within 15 mins by Western blot analysis2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
AID1528284Inhibition of LiCl-activated Wnt signaling in HEK293 cells at 3 uM by TOPFlash reporter gene assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
AID1528287Induction of mitochondrial dysfunction in human DLD1 cells assessed as reduction in mitochondrial ATP production at 3 uM by Seahorse XF real-time assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
AID1528299Uncoupling of mitochondrial oxidative phosphorylation in human DLD1 cells at 3 uM in presence of oligomycin A by seahorse XFe96 analyser based assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
AID1528291Induction of mitochondrial dysfunction in human LS174T cells assessed as reduction in mitochondrial ATP production at 3 uM by Seahorse XF real-time assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
AID1243332Inhibition of Wnt/beta catenin in human HuH7 cells assessed as [3H]-thymidine incorporation at 10 uM by scintillation counting analysis relative to DMSO-treated control2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
N-Aryl benzenesulfonamide inhibitors of [3H]-thymidine incorporation and β-catenin signaling in human hepatocyte-derived Huh-7 carcinoma cells.
AID1528306Uncoupling of mitochondrial oxidative phosphorylation in mouse liver mitochondria assessed as increase in oxygen consumption rate in presence of oligomycin A by seahorse XFe96 analyser based assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
AID1542937Growth inhibition of human SW480 cells expressing NHERF1 incubated for 72 hrs by MTT assay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Drug Design and Synthesis of First in Class PDZ1 Targeting NHERF1 Inhibitors as Anticancer Agents.
AID1528293Induction of mitochondrial dysfunction in human LS174T cells assessed as increase in glycolytic ATP production at 3 uM by Seahorse XF real-time assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
AID1542936Growth inhibition of human DLD1 cells without NHERF1 expression incubated for 72 hrs by MTT assay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Drug Design and Synthesis of First in Class PDZ1 Targeting NHERF1 Inhibitors as Anticancer Agents.
AID1528298Induction of mitochondrial membrane potential disruption in human LS174T cells measured after 2 hrs by TMRM staining based fluorescence microscopic analysis2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
AID1542938Inhibition of NHERF1 in human SW620 cells expressing NHERF1 assessed as inhibition cell growth incubated for 72 hrs by MTT assay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Drug Design and Synthesis of First in Class PDZ1 Targeting NHERF1 Inhibitors as Anticancer Agents.
AID1528285Activation of AMPK in human LS174T cells assessed as increase in AMPK phosphorylation at T172 residue at 3 uM measured within 15 mins by Western blot analysis2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
AID1667214Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 25 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1667215Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 12.5 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to contr2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1667213Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 50 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1528314Inhibition of LiCl-induced Wnt signaling in human LS174T cells assessed as reduction in beta-catenin accumulation2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
AID1528289Induction of mitochondrial dysfunction in human DLD1 cells assessed as increase in glycolytic ATP production at 3 uM by Seahorse XF real-time assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
AID1528301Uncoupling of mitochondrial oxidative phosphorylation in human DLD1 cells assessed as increase in oxygen consumption rate at 3 uM in presence of oligomycin A by seahorse XFe96 analyser based assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (2.44)29.6817
2010's36 (87.80)24.3611
2020's4 (9.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.78 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index6.85 (4.65)
Search Engine Demand Index28.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (97.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		2.5220pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		2.2110isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
4,5,6,7-tetrabromo-2-azabenzimidazole
4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor		2.0710
tyrphostin ag 1024
tyrphostin AG 1024: modulates radiosensitivity in human breast cancer cells; also an IGF1 receptor inhibitor		2.1710alkylbenzene
dan 2163
[no description available]		2.2510aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic
celecoxib
[no description available]		2.110organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
carbonyl cyanide p-trifluoromethoxyphenylhydrazone
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.		2.2110aromatic ether;
hydrazone;
nitrile;
organofluorine compound		ATP synthase inhibitor;
geroprotector;
ionophore
lapachol
lapachol : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone substituted by hydroxy and 3-methylbut-2-en-1-yl groups at positions 2 and 3, respectively. It is a natural compound that exhibits antibacterial and anticancer properties, first isolated in 1882 from the bark of Tabebuia avellanedae.		2.2510
leflunomide
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.		2.2510(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
letrozole
[no description available]		2.2110nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
lomefloxacin
lomefloxacin: structure given in first source. lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.		2.2510fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antimicrobial agent;
antitubercular agent;
photosensitizing agent
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		2.1510chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
cantharidin
Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.. cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.		2.110cyclic dicarboxylic anhydride;
monoterpenoid		EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
herbicide
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		2.1510aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
rotenone
Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.		2.2110organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.2510pyrrole;
secondary amine
pyrazolanthrone
pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.		2.110anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
thiazoles
[no description available]		2.13101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
azacitidine
Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.		2.110N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.1710taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.07101,2,3-triazole
honokiol
[no description available]		2.0810biphenyls
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		2.17103-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		2.1510methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
aspartame
[no description available]		2.2510carboxylic acid;
dipeptide zwitterion;
dipeptide;
methyl ester		apoptosis inhibitor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
environmental contaminant;
micronutrient;
nutraceutical;
sweetening agent;
xenobiotic
sb 216763
[no description available]		2.0710indoles;
maleimides
sorafenib
[no description available]		7.8330(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
wortmannin
[no description available]		2.0710acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
bortezomib
[no description available]		2.2510amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
lithium chloride
Lithium Chloride: A salt of lithium that has been used experimentally as an immunomodulator.. lithium chloride : A metal chloride salt with a Li(+) counterion.		3.2250inorganic chloride;
lithium salt		antimanic drug;
geroprotector
deoxyglucose
2-deoxy-D-glucopyranose : A 2-deoxy-D-glucose that is D-glucopyranose in which the hydroxy group at position 2 has been replaced by a hydrogen.		2.21102-deoxy-D-glucosemetabolite
eriodictyol
eriodictyol: structure. eriodictyol : A tetrahydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5, 7, 3' and 4' respectively.		2.25103'-hydroxyflavanones;
tetrahydroxyflavanone
lignans
Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)		2.0810
roflumilast
[no description available]		2.2510aromatic ether;
benzamides;
chloropyridine;
cyclopropanes;
organofluorine compound		anti-asthmatic drug;
phosphodiesterase IV inhibitor
shikonin
shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities		2.2510hydroxy-1,4-naphthoquinone
xanthohumol
xanthohumol: from hop plant, Humulus lupulus. xanthohumol : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4', a methoxy group at position 6' and a prenyl group at position 3'. Isolated from Humulus lupulus, it induces apoptosis in human malignant glioblastoma cells.		2.2510aromatic ether;
chalcones;
polyphenol		anti-HIV-1 agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor;
metabolite
sitagliptin
sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.		2.2510triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
quercetin
[no description available]		2.07107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.7930prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
luteolin
[no description available]		2.25103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
kaempferol
[no description available]		2.25107-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
galangin
5,7-dihydroxyflavonol: antimicrobial from the twigs of Populus nigra x Populus deltoides; structure in first source. galangin : A 7-hydroxyflavonol with additional hydroxy groups at positions 3 and 5 respectively; a growth inhibitor of breast tumor cells.		2.25107-hydroxyflavonol;
trihydroxyflavone		antimicrobial agent;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
plant metabolite
kaempferide
kaempferide: structure in first source. kaempferide : A monomethoxyflavone that is the 4'-O-methyl derivative of kaempferol.		2.25107-hydroxyflavonol;
monomethoxyflavone;
trihydroxyflavone		antihypertensive agent;
metabolite
morin
morin: a light yellowish pigment found in the wood of old fustic (Chlorophora tinctoria). morin : A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5.		2.25107-hydroxyflavonol;
pentahydroxyflavone		angiogenesis modulating agent;
anti-inflammatory agent;
antibacterial agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
hepatoprotective agent;
metabolite;
neuroprotective agent
myricetin
[no description available]		2.07107-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
scutellarein
scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein. scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.		2.2510tetrahydroxyflavonemetabolite
wogonin
wogonin: structure in first source. wogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.		2.2510dihydroxyflavone;
monomethoxyflavone		angiogenesis inhibitor;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
plant metabolite
daidzein
[no description available]		2.25107-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
lysophosphatidic acid
lysophosphatidic acid: RN given refers to parent cpd. 1-oleoyl-sn-glycerol 3-phosphate : A 1-acyl-sn-glycerol 3-phosphate having oleoyl as the 1-O-acyl group.. lysophosphatidic acid : A member of the class of lysophosphatidic acids obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid. A 'closed' class.		2.04101-acyl-sn-glycerol 3-phosphate
licochalcone a
licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer		2.2510chalcones
casein kinase ii
Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.		2.0710
ag-490
[no description available]		2.3110catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide		anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor
nifuroxazide
nifuroxazide: structure		2.2510benzoic acids
taxane
taxane: produced by Taxomyces andreanae		2.110diterpene;
terpenoid fundamental parent
icg 001
[no description available]		2.2110peptide
3-methylbutanoic acid [(2R,3S,6S,7R)-3-[[(3-formamido-2-hydroxyphenyl)-oxomethyl]amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] ester
[no description available]		2.2110N-acyl-amino acid
mobic
Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.		2.58201,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
a 769662
[no description available]		2.2110biphenyls
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		2.1710
(r)-pfi-2
(R)-PFI-2: a potent and selective inhibitor of SETD7 methyltransferase; structure in first source		2.2510
cyclin d1
Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.		3.0340
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		02.5720
Colonic Neoplasms
Tumors or cancer of the COLON.		02.5720
Diabetic Glomerulosclerosis
[description not available]		02.6320
Cirrhosis
[description not available]		02.3110
Diabetic Nephropathies
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.		02.6320
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		02.3110
Experimental Neoplasms
[description not available]		02.3110
Cancer of Pancreas
[description not available]		03.7630
Lentiginosis, Perioral
[description not available]		02.3110
Cystadenoma, Mucinous
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.		02.3110
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		03.7630
Peutz-Jeghers Syndrome
A hereditary disease caused by autosomal dominant mutations involving CHROMOSOME 19. It is characterized by the presence of INTESTINAL POLYPS, consistently in the JEJUNUM, and mucocutaneous pigmentation with MELANIN spots of the lips, buccal MUCOSA, and digits.		02.3110
Cancer of Stomach
[description not available]		02.5720
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.5720
Disease Exacerbation
[description not available]		02.1710
Carcinoma, Papillary
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)		02.1710
Lymph Node Metastasis
[description not available]		02.1710
Cancer of the Thyroid
[description not available]		02.1710
Thyroid Neoplasms
Tumors or cancer of the THYROID GLAND.		02.1710
Invasiveness, Neoplasm
[description not available]		03.3860
Chronic Kidney Diseases
[description not available]		02.1710
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)		02.1710
Colorectal Cancer
[description not available]		07.2110
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.2110
Hepatocellular Carcinoma
[description not available]		03.3860
Cancer of Liver
[description not available]		03.3860
Experimental Hepatoma
[description not available]		02.2110
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		03.3860
Liver Neoplasms
Tumors or cancer of the LIVER.		03.3860
Cancer of Prostate
[description not available]		02.2110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.2110
Triploid
[description not available]		02.2110
Carcinoma, Non-Small Cell Lung
[description not available]		02.4920
Cancer of Lung
[description not available]		02.7830
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.4920
Lung Neoplasms
Tumors or cancer of the LUNG.		02.7830
Metastase
[description not available]		02.110
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.110
Lung Adenocarcinoma
[description not available]		02.110
Adenocarcinoma, Basal Cell
[description not available]		02.110
Adenocarcinoma of Lung
A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.		02.110
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.110
Proliferative Vitreoretinopathy
[description not available]		02.110
Vitreoretinopathy, Proliferative
Vitreoretinal membrane shrinkage or contraction secondary to the proliferation of primarily retinal pigment epithelial cells and glial cells, particularly fibrous astrocytes, followed by membrane formation. The formation of fibrillar collagen and cellular proliferation appear to be the basis for the contractile properties of the epiretinal and vitreous membranes.		02.110
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.110
Degenerative Disc Disease
[description not available]		02.1110
Calcification, Pathologic
[description not available]		02.1110
Calcinosis
Pathologic deposition of calcium salts in tissues.		02.1110
Intervertebral Disc Degeneration
Degenerative changes in the INTERVERTEBRAL DISC due to aging or structural damage, especially to the vertebral end-plates.		02.1110
Esophageal Squamous Cell Carcinoma
A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.		02.1110
Carcinoma, Epidermoid
[description not available]		02.1110
Cancer of Esophagus
[description not available]		02.1110
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.1110
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		02.1110
Breast Cancer
[description not available]		07.4920
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.4920
Angiogenesis, Pathologic
[description not available]		03.0410
Benign Neoplasms, Brain
[description not available]		02.1510
Glial Cell Tumors
[description not available]		02.5120
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.1510
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.5120
Granulocytic Leukemia
[description not available]		02.1510
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.		02.1510
Biliary Tract Cancer
[description not available]		02.0710
Biliary Tract Neoplasms
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.		02.0710
Chromosomal Translocation
[description not available]		02.0710